Recent advances in the development of vaccines for Ebola virus disease

Virus Research

Volumn 211, Issue , 2016, Pages 174-185

  Ohimain, Elijah Ige ^a  

^a NIGER DELTA UNIVERSITY   (Nigeria)

Author keywords

Hemorrhagic fever; Pre existing immunity; Replication competent vaccine; Replication incompetent vaccine; Zoonotic infections

Indexed keywords

ADENOVIRUS VACCINE; DNA VACCINE; EBOLA VACCINE; INACTIVATED VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS LIKE PARTICLE VACCINE;

DRUG SCREENING; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; HUMAN; HUMAN PARAINFLUENZA VIRUS 3; NONHUMAN; PRIORITY JOURNAL; RABIES VIRUS; REPLICON; REVIEW; VACCINIA VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VESICULOVIRUS; VIRUS GENOME; ANIMAL; CLINICAL TRIAL (TOPIC); GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; VIROLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84951848907     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2015.10.021     Document Type: Review

References (125)

1. Adegun O. The effects of Ebola virus on the economy of West Africa through the trade channel. IOSR J. Humanit. Soc. Sci. 2014, 19(10):48-56.
2. ADI, 2014. Ebola and Marburg virus vaccine Elisa Kits, recombinant protein and antibodies. Alpha Diagnostic Laboratories. USA. pp. 1-8. (accessed 9.10.15.). http://https://4adi.com/objects/catalog/product/extras/AE-320800-Ebola-virus-antigen-elisa-kit.pdf.
3. ASPR, 2015. Ebola vaccine landscape. United States department of human and human services. (accessed 9.10.15.). http://https://www.google.com/url%3Fsa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CBwQFjAAahUKEwiL3NiFoLbIAhUJBSwKHaP5ApI&url=http%3A%2F%2Fwho.int%2Fmediacentre%2Fevents%2F2015%2FS2.4_Robinson_ebola_MCM_landscape.pdf&usg=AFQjCNGs1rYtcoWjCFDSKxo1WT-VZySBgA&sig2=WYLvEzyAB1dqBD8EwTV8FA&bvm=bv.104819420,d.d24.
4. Bausch D.G. One step closer to an Ebola virus vaccine. Engl. J. Med. 2014. (accessed 9.10.15.). http://www.nejm.org/doi/full/10.1056/NEJMe1414305.
5. Bavarian Nordic, 2015. Bavarian Nordic announces initiation of phase 1 clinical trial for the Ebola vaccine regimen of MVA-BN Filo and Janssen's AdVac technology. (accessed 9.10.15.). http://www.bavarian-nordic.com/investor/news/news.aspx%3Fnews=4556.
6. Beeching N.J., Fenech M., Houlihan C.F. Ebola virus disease. BMJ 2014, 349:g7348.
7. Bente D., Gren J., Strong J.E., Feldmann H. Disease modelling for Ebola and Marburg viruses. Dis. Models Mech. 2009, 2:12-17.
8. Bishop B.M. Potential and emerging treatment options for Ebola virus disease. Ann. Pharmacother. 2015, 49:196-206.
9. Blaney J.E., Marzi A., Willet M., Papaneri A.B., et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with Rabies virus based bivalent vaccine. PLoS Pathog. 2013, 9(5):e1003389.
10. Blaney J.E., Wirblich C., Papaneri A.B., Johnson R.F., et al. Inactivated or live- attenuated bivalent vaccines that confer protection against Rabies and Ebola viruses. J. Virol. 2011, 85(20):10605-10616.
11. Bukreyev A., Marzi A., Feldmann F., Zhang L., Yang L., et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009, 383(2):348-361.
12. Bukreyev A.A., Rolin P.E., Tate M.K., Yang L., et al. Successful tropical respiratory tract immunization of primates against Ebola virus. J. Virol. 2007, 81(12):6379-6388.
13. Bukreyev A.A., Yang L., Zaki S.R., Shiech W.-J., et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 2006, 80(5):2267-2279.
14. Bukreyev A.A., Chandran K., Dolnik O., Dye J.M., Ebihara H., et al. Discussions and decisions of the 2012-2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae study group, January 2012-June 2013. Arch. Virol. 2014, 159:821-830.
15. Butler D. Ebola drug trials set to begin amid crises. Nature 2014, 513:13-14.
16. Cheto M. West Afica: economic implications of Ebola outbreak for affected countries. Teneo Intelligence 2014, (accessed 9.10.2015.).
17. Chigbu U.E., Ntiador A.M. Ebola in West Africa: implications on community interaction in urban Nigeria. Int. J. Educ. Res. 2014, 2(10):329-346.
18. Choi J.H., Jonsson-Schmunk K., Qiu X., Shedlock D.J., et al. A single dose respiratory recombinant Adenovirus-based vaccine provided long-term protection for non-human primates from lethal Ebola infection. Mol. Pharm. 2015, 12(8):2712-2731.
19. Clarke D.K., Nasar F., Lee M., Johnson J.E., Wright K., Calderon P., et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J. Virol. 2007, 81(4):2056-2064.
20. Dhama K., Malik Y.S., Malik S.V.S., Singh R.J. Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives. J. Infect. Dev. Countries 2015, 9(5):441-455.
21. Enterlein S., Warfield K.L., Swenson D.L., Stein D.A., et al. VP 35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 2006, 50(3):984-993.
22. Falzarano D., Geisbert T.W., Feldmann H. Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev. Vaccines 2011, 10(1):63-77.
23. Feldmann H., Jones S., Klenk H., Schnitter H. Ebola virus: from discovery to vaccine. Nat. Rev. 2003, 677-685. August.
24. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Ströher U., Grolla A., Bray M., Fritz E.A., Fernando L., Feldmann F., Hensley L.E., Geisbert T.W. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007, 3(1):e2.
25. Feldmann H., Geisbert T. Ebola haemorrhagic fever. Lancet 2011, 377:849-862.
26. Friedrich M.B., Trefry J.C., Biggins J.E., Hensley L.E., et al. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 2012, 4:1619-1650.
27. Galvani A.P., Ndeffo-Mbah M.L., Wenzel N., Childs J.E. Ebola vaccination: if not now, when?. Ann. Intern. Med. 2014, 161(10):749-751.
28. Geisbert T.W., Daddario-DiCaprio K.M., Wiliams K.J.N., Geisbert J.B., et al. Recombinant vesicular stomatitis virus vector mediates post exposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol. 2008, 82(11):5664-5668.
29. Geisbert T.W., Kathleen M., Daddario-DiCaprio K.M., Lewis M.G., et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008, 4(11):e1000225.
30. Geisbert T.W., Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J. Infect. Dis. 2011, 204:S1075-S1081.
31. Geisbert T.W., Lee A.C.H., Robbins M., et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010, 375:1896-1905.
32. Geo-Vax Lab Inc., 2014. GeoVax announces initiation of Ebola vaccine development program. GeoVax (accessed 9.10.15.). http://www.geovax.com/news-events/entry/2014/10/02/geovax-announces-initiation-of-ebola-vaccine-development-program.html.
33. Gibert S. Clinical development of modified vaccinia virus Ankara vaccine. Vaccine 2013, 31(39):4241-4246.
34. Greffex, Inc., 2014. A trivalent Ebola-Marburg vaccine constructed as a final generation fully deleted Adenovirus vectored. (accessed 9.10.15.).
35. Gunther S., Feldman H., Geisbert T.W., Hensley L.E., et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J. Infect. Dis. 2011, 204:S785-S790.
36. Hensley L.E., Mulangu S., Asiedu C., Johnson J., et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebola virus species. PLoS Pathog. 2010, 6(5):e1000904.
37. Herbert A.S., Kuehne A.I., Barth J.F., Ortiz R.A., et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with Ebola virus. J. Virol. 2013, 87(9):4952-4964.
38. Hoenen T., Feldmann H. Ebola virus in West Africa, and the use of experimental therapies or vaccines. BMC Biol. 2014, 12:80.
39. Hoenen T., Groseth A., Feldmann H. Current Ebola vaccines. Expert Opin. Biol. Ther. 2012, 12(7):859-872.
40. HUG, 2014. Tested at the University of Geneva, the Canadian experimental Ebola vaccine is well tolerated by volunteers. University of Geneva press release 2 December 2014. <> (accessed 9.10.15). http://https://www.google.com.ng/url%3Fsa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CBsQFjAAahUKEwjSnNK0k7nIAhVE1xQKHROfDgo&url=http%3A%2F%2Fwww.hug-ge.ch%2Fsites%2Finterhug%2Ffiles%2Fpresse%2Fcommunique_vaccin_ebola_2_12_2014_anglais.pdf&usg=AFQjCNFfuP4iOYLA8lPAxR4-j-Xtt-nMeQ&bvm=bv.104819420,d.d24/.
41. Jacobs B.L., Langland J.O., Kibler K.V., Denzler K.L., et al. Vaccinia virus vaccines: past, present and future. Antivir. Res. 2009, 84(1):1-13.
42. Kanapathipillai R., Restrepo A.M.H., Fast P., Wood D., et al. Ebola vaccine-an urgent international priority. New Engl. J. Med. 2014, 10.1056/NEJMp1412166.
43. Kibuuka H., Berkowitz N.M., Milllard M., Enama M.E., et al. Safety and innunogencity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Uganda adults: a phase 1b, randomized double-blind, placebo-controlled chemical trial. Lancet 2015, 385(9977):1545-1554.
44. Kobinger G.P., Feldmann H., Zhi Y., Schumer G., et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006, 346:394-401.
45. Kondratowicz A.S., Maury W.J. Ebola virus: a brief review of novel therapeutic targets. Future Microbiol. 2012, 7(1):1-4.
46. Kortepeter M.G., Bausch D.G., Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J. Infect. Dis. 2011, 204:S810-S816.
47. Kreijtz J.H.C.M., Goeijenbier M., Moesker F.M., van den Dries L., et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomized, double-blind phase 1/2a clinical trial. Lancet Infect. Dis. 2014, 14(12):1196-1207.
48. Lai K.Y., Ng G.W.Y., Cheng F. Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect. Dis. Poverty 2014, 3:43-60. 10.1186/2049-9957-3-43.
49. Ledgerwood J.E., DeZure A.D., Stanley D.A., Novik L., et al. Chimpanzee Adenovirus vector Ebola vaccine-preliminary report. N. Engl. J. Med. 2014, 1-9. (accessed 9.10.15.).
50. Ledgerwood J.E. Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort. Lancet 2015, 15:1117-1119.
51. Leung D.W., Prins K.C., Borek D.M., Farahbakhsh M., Tufariello J.M., Ramanan P., Nix J.C., Helgeson L.A., Otwinowski Z., Honzatko R.B., Basler C.F., Amarasinghe G.K. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 2010, 17(2):165-172.
52. Lupton H.W., Lambert R.D., Bumgardner D.L., Moe J.B., Eddy G.A. Inactivated vaccine for Ebola virus efficacious in guinea pig model. Lancet 1980, 1294-1295.
53. Marston H.D., Folkers G.K., Morens D.M., Fauci A.S. Emerging viral disease: confronting threats with new technologies. Sci. Transl. Med. 2014, 6. 253ps10. http://stm.sciencemag.org/content/6/253/253ps10.full-text.pdf+html/> (accessed 9.10.15.).
54. Martin J.E., Sullivan N.J., Enama M.E., Gordon I.J., et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin. Vaccine Immunol. 2006, 13(11):1267-1277.
55. Martinez O., Tantral L., Mulherkar N., Chandran K., et al. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J. Infect. Dis. 2011, 204:S825-S832.
56. Marzi A., Ebihara H., Callison J., Groseth A., et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J. Infect. Dis. 2011, 204:S1066-S1074.
57. Marzi A., Englemann F., Feldmann F., Haberthur K., et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. PNAS 2013, 100(5):1893-1898.
58. Mellquist-Riemenschneider J.L., Garrison A.R., Geisbert J.B., Saikh K.U., et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res. 2003, 92:187-193.
59. Meyer M., Garron T., Lubaki N.M., et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J. Clin. Invest. 2015, 125(8):3241-3255.
60. Mire C.E., Geisbert J.B., Agans K.N., Satterfield B.A., et al. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates. PLoS One 2014, 9(4):e94355.
61. Mire C.E., Geisbert J.B., Marzi A., Agans K.N., et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl. Trop. Dis. 2013, 7(12):e2600.
62. Mire C.E., Demetrius Matassov, Joan B., Geisbert, Theresa E., Latham, Krystle Agans N., Rong Xu, Ayuko Ota-Setlik, Egan Michael A., Fenton Karla A., Clarke David K., Eldridge John H., Eldridge, Geisbert Thomas W. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 2015, 520:688-691.
63. Mire C.E., Geisbert T.W. Viral-vectored vaccines to control pathogenic filoviruses. Novel Technologies for Vaccine Development 2014, 33-60. Springer-Verlag, Wien. I.S. Lukashevich, H. Shirwan (Eds.).
64. Mire C.E., Miller A.D., Carville A., Westmoreland S.V., et al. Recombinant vesicular stomatitis vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl. Trop. Dis. 2012, 6(1):e1567.
65. Norwegian Institute of Public Health, 2014. Discussion note for the WHO urgent Ebola vaccine access meeting. Norwegian Institute of Public Health. (accessed 9.10.2015.).
66. Ohimain E.I. How the spread of Ebola virus was curtailed in Nigeria. Int. J. Med. Pharm. Case Rep. 2015, 4(1):11-20.
67. Olinger G.G., Bailey M.A., Dye J.M., Bakken R., et al. Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J. Virol. 2005, 79(22):14189-14196.
68. Olinger G.G., Pettitt J., Kim D., Working C., et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. PNA 2012, 109(44):18030-18035.
69. Onwuakor C.E. Ebola outbreak in Africa: current issues-a mini review. Am. J. Med. Case Rep. 2014, 2(9):184-186.
70. Papaneri A.B., Wirblich C., Cooper K., Jahrling P.B., et al. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine 2012, 30:6136-6141.
71. Patel A., Zhang Y., Croyle M., Tran K., et al. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J. Infect. Dis. 2007, 196:S413-S420.
72. Peters C.J., Feldmann S.H., Rollin P.E., Nichol S., Ksiazek T.G. Filoviruses as emerging pathogens. Semi. Virol. 1994, 5:147-154.
73. PHAC, 2014. Canada's Ebola vaccine. Public Health Agency of Canada. (accessed 9.10.2015.). http://www.phac-aspc.gc.ca/id-mi/vsv-ebov-fs-eng.php.
74. Phoolcharoen W., Dye J.M., Kilbourne J., Piensook K., et al. A non replicating subunit vaccine protect mice against lethal Ebola virus challenge. PNAS 2011, 108(51):1432-1433.
75. Pratt W.D., Wang D., Nichols D.K., Luo M., et al. Protection of nonhuman primates against two species of EBOLA virus infection with a single complex Adenovirus vector. Clin. Vaccine Immunol. 2010, 17(4):572-581.
76. Price P.J.R., Toree-Dominguez C., Brandmuller C., Sutter G., Lehmann M.H. Modified vaccinia Ankara: inate immune activation and induction of cellular signaling. Vaccine 2013, 31(39):4231-4234.
77. Pushko P., Bray M., Ludwig G.V., Parker M., et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000, 19(1):142-1453.
78. Pushko P., Geisbert J., Parker M. Individual and bivalent vaccines based on Alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 2001, 75(23):11677-11685.
79. Qiu X., Audet J., Wong G., Fernando L., et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci. Rep. 2013, 3. 10.1038/srep03365.
80. Qiu X., Audet J., Wong G., Pillet S., et al. Successful treatment of Ebola virus ?infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 2012, 4(138). (accessed 11.10.15.).
81. + T cells. J. Virol. 2002, 76(18):9176-9185.
82. Reid S.P., Valmas C., Martinez O., Sanchez F.M., Basler C.F. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 2006, 81(24):13469-13477.
83. Reynard O., Mokhonova M.E., Leung J., Page A., et al. Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J. Infect. Dis. 2011, 204:S1060-S1065.
84. Richardson J.S., Dekker J.D., Croyle M.A., Kobinges G.P. Recent advances in Ebola virus vaccines development. Hum. Vaccin. 2010, 6(6):439-449.
85. Richardson J.S., Wong G., Pillet S., Schindle S., et al. Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents. J. Bioterror. Biodef. 2011, S1:007. 10.1016/j.tim.2014.04.002.
86. Richardson J.S., Yao M.K., Tran K.N., Croyle M.A., et al. Enhanced protection against Ebola virus mediated by an improved Adenovirus-based vaccine. PLoS One 2009, 4(4):e5308.
87. Salaam-Blyther, T., 2014. US and international health responses to the Ebola outbreak in West Africa Congressional research service. (accessed 9.10.15.). http://https://www.google.com.ng/url%3F.sa=t&rct=j&q=&esrc=s&source=web&cd=3&cad=rja&uact=8&ved=0CCcQFjACahUKEwjloOzC8brIAhXKVxoKHd7nDk8&url=http%3A%2F%2Ffpc.state.gov%2Fdocuments%2Forganization%2F231281.pdf&usg=AFQjCNEGh52HqhB4QjRVxd1b6GOlEO0G5w&bvm=bv.104819420,d.d24.
88. Sarwar W.W., Costner P., Enama M.E., Berkowitz N., et al. Safety and immunogenicity of DNA vaccines encoding Ebola virus and Marburg wild-type glycoproteins in a phase I clinical trial?. J. Infect. Dis. 2015, 211(4):549-557.
89. Shedlock D.J., Aviles J., Taboth K.T., Wong G., et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol. Ther. 2013, 21(7):1432-1444.
90. Shuaib F., Gunala R., Musa E.O., Mahoney F.J., et al. Ebola virus disease outbreak-Nigeria, July-September 2014. Morb. Mortal. Wkly. Rep. 2014, 63(39):867-872.
91. Skenderi F., Jonjic S. Viral vaccines and vectors-some lessons from cytomegaloviruses. Period. Biol. 2012, 114(2):201-210.
92. Smith, G., 2014. Novavax annunouces Ebola vaccines development programme at the 8th vaccine and ISV conference, Philadelphia. (accessed 9.10.15.). http://ir.novavax.com/phoenix.zhtml%3Fc=71178&p=irol-newsArticle&ID=1981603.
93. Smith L.R., Wloch M.K., Chaplin J.A., Gerber M., et al. Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial. Vaccines 2013, 1:398-414.
94. Sobarzo A., Perelman E., Groseth A., et al. Profiling the native specific human humoral immune response to Sudan Ebola virus strain gulu by chemiluminescence enzyme-linked immunosorbent assay. Clin. Vaccine Immunol. 2012, 19(11):1844-1852.
95. Stanley D.A., Honko A.N., Asiedu C., Trefry J.C., et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebola virus challenge. Nat. Med. 2014, 20(10):1126-1129.
96. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408(6812):605-609.
97. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., et al. Immune protection of nonhuman primates against Ebola virus with single low-dose Adenovirus vectors encoding modified GPs. PLoS Med. 2006, 3(6):e177.
98. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424:681-684.
99. Swenson D.L., Wang D., Luo M., Warfield K.L., et al. Vaccine to confer to nonhuman primates complete protection against Multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 2008, 15(3):460-467.
100. Takada A., Feldmann H., Stroeher U., Bray M., et al. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 2003, 77(2):1069-1074.
101. Tayo A.S., Adeoye A.O., Olaore B., Ojewole O.A., Babalola J.A.O. Psycho social implication of infiltration of Ebola virus disease into Nigeria: religious and counselling perspective. Eur. J. Res. Soc. Sci. 2015, 3(1):11-19.
102. The Economist, 2015. Ebola graphics: the toll of tragedy. The Economist January 2015. (accessed 9.10.15.). http://www.economist.com/blogs/graphicdetail/2015/08/ebola-graphics%3Fpage=1&fsrc=rss.
103. Trunschke M., Conrad D., Enterlein S., Olejnik J., Brauburger K., Mühlberger E. The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology 2013, 441(July (2)):135-145. Epub 2013 April 11. 10.1016/j.virol.2013.03.013.
104. Tsuda Y., Caposio P., Parkins C.J., Botto S., et al. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL Epitope confers protection against Ebola virus. PLoS Negl. Trop. Dis. 2011, 5(8):e1275.
105. Wahren B., Liu M.A. DNA vaccines: recent developments and the future. Vaccines 2014, 2:785-796.
106. Wang D., Raja N.U., Trubey C.M., Juompan L.Y., et al. Development of a cAdVax-based bivalent Ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J. Virol. 2006, 80(6):2738-2746.
107. Wang Y., Liu Z., Dai Q. A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody. Virus Res. 2014, 189:254-261.
108. Warfield K.L., Aman M.J. Advances in virus-like particle vaccine for Filoviruses. J. Infect. Dis. 2011, 204:S1053-S1059.
109. Warfield K.L., Posten N.A., Swenson D.L., Olinger G.G., et al. Filovirus like particles produced in insect cells: immunogenicity and protection in rodents. J. Infect. Dis. 2007, 196:S421-S429.
110. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., et al. Ebola virus-like particle-based vaccine protects nonhuman primatesaginst lethal Ebola virus challenge. J. Infect. Dis. 2007, 196:S430-S437.
111. Watanabe S., Noda T., Halfmann P., Jasenosky L., et al. Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J. Infect. Dis. 2007, 196:284-290.
112. Watanabe S., Watanabe T., Noda T., Takada A., et al. Production of novel Ebola vaccine-like particles from cDNAs: an alternative to Ebola virus generation by reverse genetics. J. Virol. 2004, 78(2):999-1005.
113. WHO Background Document Potential Ebola Therapies and Vaccines 2014, World Health Organization, Rome, Italy, (accessed 9.10.15).
114. WHO Potential Ebola therapies and vaccines 2014, World Health Organization, Rome, Italy, (accessed 9.10.15.).
115. WHO New therapeutics and preventive medicines to fight the Ebola epidemic 2014, World Health Organization, Rome, Italy, (accessed 9.10.15.).
116. WHO Ebola Situation report 19 August 2015 2015, World Health Organization, Rome, Italy, (accessed 9.10.15.).
117. WHO Ebola Response Team Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N. Engl. J. Med. 2014, 371:1481-1495.
118. Wilson J.A., Bray M., Barkken R., Hart M.K. Vaccine potential of Ebola virus VP24, VP30, VP 35, and VP40 proteins. Virology 2001, 286:384-390.
119. World Bank, 2014. The economic impact of the 2014 Ebola epidemic: short and medium term estimate for Guinea, Liberia and Sierra Leone. Report no. 90748. (accessed 27.10.15.). http://www.worldbank.org/en/region/afr/publication/the-economic-impact-of-the-2014-ebola-epidemic-short-and-medium-term-estimates-for-west-africa.
120. Wong G., Audet J., Fernando L., et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014, 32(43):5722-5729.
121. Yang Y., Ertl H.C., Wilson J.M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant Adenoviruses. Immunity 1994, 1(5):433-442.
122. Yang Y., Li Q., Ertl H.C., Wilson J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 1995, 69(4):2004-2015.
123. Yang Y., Greenough K., Wilson J.M. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 1996, 3(5):412-420.
124. Yang L., Sanchez A., Ward J.M., Murphy B.R., et al. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology 2008, 377(2):255-264.
125. Yelle J. The 2014 Ebola virus outbreak in West Africa: current perspectives for prevention and treatment. J. Hum. Virol. Retrovirol. 2014, 1(4). 00024.